Medical need is the start of every development process. We identify a therapeutic gap in the provision of healthcare and set out to find a solution – and we keep at it until we can fill that gap and offer patients something others don’t. That’s how ideas and active ingredients become effective medications.
Taking an initial idea as the basis for a new product, the Research & Development department goes into action. Our developers use well-documented substances as they search for ways to improve the availability of active ingredients or use new mechanisms of action to help. One crucial question that arises early in the development process is the optimum form – pill or powder, liquid or syrup, suppository or patch? There are a whole host of possibilities.
Acting on our own initiative, we have developed a number of highly successful products that are marketed in domestic and international markets. The history of our GeloRevoice® and NYDA® brands shows just how much staying power our innovative drive has: NYDA® lice treatment is the market leader in Germany, and GeloRevoice® throat tablets are very popular among singers and others who use their voices a great deal.
Focusing on the patient
All medical products are required to prove their efficacy and tolerability in extensive studies for both new medications and those that have already been approved. All of these studies follow rules of Good Clinical Practice (GCP), a set of internationally recognized guidelines for performing clinical studies. Protecting participants and the quality of study results are key areas of focus.
We turn ideas into successful products.
25
years. Over this time, we have conducted 150 clinical trials with more than
14,000 participants.
14,000 participants.